Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Flamel Technologies to initiate phase I study of Basulin

Oct. 6, 1999

New study indicates another potential indication for pentoxifylline

Oct. 6, 1999

Novartis pursues development of Src kinase inhibitors for osteoporosis

Oct. 6, 1999

Novo Nordisk investigates new strategy for diabetes and its complications: normoglycemic agents

Oct. 5, 1999

SmithKline Beecham reports advances in vitronectin receptor antagonist research

Oct. 5, 1999

Integrin antagonist S-787 prevents ovariectomy-induced bone loss in rats

Oct. 5, 1999

ASBMR participants learn of efficacy, safety of risedronate in several large studies

Oct. 5, 1999

Compound from Streptomyces inhibits bone resorption, induces apoptosis in osteoclasts in vitro

Oct. 4, 1999

Geranylgeranyltransferase inhibition as a mechanism for specifically inhibiting bone resorption

Oct. 4, 1999

BMS seeks FDA approval for novel oral antidiabetic drug

Oct. 4, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...